Objectives

After participating in this educational activity, attendees should be able to:

1. Recognize current knowledge of how the GH/IGF-1 axis contributes to the pathophysiology of NAFLD/NASH through preclinical models and patients with hypopituitarism
2. Identify obesity as a state of relative GH deficiency
3. Recognize the potential to leverage the GH/IGF-1 axis in the treatment of NAFLD/NASH in patients with obesity-associated NAFLD

Faculty

Laura, Dichtel, MD MHS
Assistant Professor
Harvard Medical School
Massachusetts General Hospital 

Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education ( CE ) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options.  Faculty or planner conflicts of interest are resolved before the educational activity.

None of the members of the planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.

Dr. Dichtel - Grant Support:  Drug donation for investigator - initiated study (Pfizer) & Scan analysis donated for investigator  research project ( Perspectium Diagnostics)